- XNCR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.4 million.
- XNCR has traded 124,227 shares today.
- XNCR is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in XNCR with the Ticky from Trade-Ideas. See the FREE profile for XNCR NOW at Trade-Ideas More details on XNCR: Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Currently there are 3 analysts that rate Xencor a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Xencor has been 193,700 shares per day over the past 30 days. Xencor has a market cap of $871.0 million and is part of the health care sector and drugs industry. Shares are up 31% year-to-date as of the close of trading on Friday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Xencor as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income.